BioCorRx Q2 FY26 net loss narrows to $1 million; revenue drops 50.6% to $87,970
Reuters2026/08/14 16:34- BioCorRx posted a net loss of USD 1.00 million for the quarter ended June 30, 2026, narrowing from USD 1.38 million.
- Revenue fell 50.6% to USD 87,970 versus the prior-year quarter, on lower Lucemyra distribution sales.
- Grant income more than doubled to USD 679,477, while operating expenses edged down to USD 1.55 million.
- Cash totaled USD 21,237 at June 30, 2026; net cash used in operating activities was USD 873,260 for the six months ended June 30, 2026.
- Working capital deficit stood at USD 8.23 million, with management flagging substantial doubt about going-concern over the next 12 months.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ivy League’s space gamble: Harvard reveals $2.2 billions SpaceX position, its largest single stock holding
Harvard University Investment Management Company disclosed that it holds $2.2 billion worth of SpaceX shares, making it the largest single stock position in its $4.3 billion US equity portfolio. This holding originated from Harvard’s early investment in SpaceX through venture capital funds, and the position has significantly appreciated after SpaceX’s public listing in June this year. The University of California also disclosed a roughly $1 billion position in SpaceX during the same period. Over the past decade, endowment funds from several universities have made substantial bets on private tech assets.
Circle obtains Major Payment Institution license in Singapore
Crypto prices
More
